The growth of 3-drug combinations has slowed down in the hypertension/hyperlipidemia combination drug market. After recording double-digit YoY growth every quarter until the first half of last year, the spurt has slowed sharply since the end of last year.

On the other hand, the 4-drug combinations that newly entered the market are rapidly expanding their influence. Prescription sales of Hanmi Pharm’s Amosartan XQ, which is leading the growth of 4-drug combinations, are expected to exceed KRW 10 billion in annual prescriptions.

Brakes pulled on the growth of 3-drug combos…rate of growth reduced

According to the market research institution UBIST, the outpatient prescrip